Ironwood Pharmaceuticals Inc (FRA:I76)
€ 4.5 -0.04 (-0.88%) Market Cap: 713.95 Mil Enterprise Value: 1.21 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Ironwood Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 07:20PM GMT
Release Date Price: €10.6
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

On the Specialty Pharmaceuticals pack for the day, it's my pleasure to have the management team from Ironwood with us. With me, I have Sravan Emany, the CFO; and Mike Shetzline, the Chief Medical Officer. And my name is Balaji Prasad, so I lead the specialty pharmaceuticals coverage for Barclays. Sravan and Mike, thank you for taking the time today to be with us. It's great to do it in person too, so.

Sravan Kumar Emany
Ironwood Pharmaceuticals, Inc. - Senior VP & CFO

Absolutely.

Questions & Answers

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

So let me first start with the core franchise rights, LINZESS. It continues to perform very well. It's near tenth year since you launched, and now we have guided to double-digit demand growth, prescription demand growth. So what's driving this trend? And how confident are you of ensuring that this is sustainable. And of course, I -- my apologies also if you have an opening

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot